Paraoxonase Activity as a Biochemical Indicator of Dyslipidaemia in Diabetes Mellitus Type 2 and Ischemic Heart Disease

被引:0
|
作者
Ismail, Aziza [1 ]
Hassan, Mohamed Fathallah M. [2 ]
Abdelfattah, Mohy Eldin [2 ]
Hassan, Fathallah M. [3 ]
机构
[1] Suez Canal Univ, Dept Chem, Fac Sci, Ismailia, Egypt
[2] Suez Canal Univ, Fac Med, Dept Internal Med, Ismailia, Egypt
[3] Suez Canal Univ, Fac Med, Dept Biochem, Ismailia, Egypt
关键词
Apolipoprotein A1; Dyslipidemia; Non-insulin dependent diabetes mellitus; Ischemic heart disease; Oxidative stress; Paraoxonase1;
D O I
暂无
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Mammalian paraoxonases (PONs) are a group of enzymes of calcium-dependent, esterases consisting of Paraoxonase-1, 2 and 3 Paraoxonase. But, PON1 has the dominant PON activity in blood. It is synthesized by the liver and found in the circulation associated with high-density lipoproteins (HDL). It protects low density lipoprotein (LDL) and HDL from lipid peroxidation. Alterations in circulating PON1 level have been reported in a variety of diseases involving oxidative stress including non-insulin dependent diabetes mellitus (NIDDM) and ischemic heart disease (IHD). The aim of this work has been planned to demonstrate PON1 activity in different diseases associated with dyslipidemia as NIDDM and IHD. This study was carried out on 20 Patients with NIDDM (NIDDM group) and 20 patients admitted to the Cardiac Care Unite with IHD (IHD group) in addition to 20 healthy subjects free from any disease as control group. All groups were selected from Suez Canal University Hospital. They were subjected to full history tacking and assay of fasting blood sugar, lipid profile and liver function tests using colorimetric methods. In addition, PON1 activity was measured using paraoxon as a substrat and apolipoprotein A1 (ApoA1) was measured using nephlometric method. Our results showed that patients with NIDDM and IHD had higher BMI, they were dyslipidemic where cholesterol, triglycerides and low density lipoprotein were higher and HDL was lower in the two patients groups compared to the control. In addition PON1 activity and ApoA1 were decreased in the two patients groups compared to the control. A positive correlation was found between PON1 and ApoA1 in the two patient's groups. Conclusions: PON1 activity and ApoA1 were reduced in Diabetes mellitus and Ischemic heart disease patients compared to the controls. Dyslipidemia is associated with patients of mentioned diseases with higher body mass index.
引用
收藏
页码:107 / 113
页数:11
相关论文
共 50 条
  • [41] Ischemic Heart Disease by thallium scintigraphy in type 2 diabetes mellitus and control asymptomatic subjects.
    Castells, I
    Rius, F
    Rubio, L
    Fraile, M
    Pereferrer, D
    Salinas, I
    Romero, R
    Sanmarti, A
    DIABETOLOGIA, 1998, 41 : A343 - A343
  • [42] Metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency
    Kravchuk, E. N.
    Galagudza, M. M.
    DIABETES MELLITUS, 2013, 16 (01): : 5 - 14
  • [43] Effect of type 2 diabetes mellitus and mutations of the cyp2c19 gene on the platelets functional activity of patients with ischemic heart heart disease
    Netiazhenko, V.
    Karpenko, O.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1097 - 1097
  • [44] Paraoxonase 192 Q/R gene polymorphism, enzyme activity and coronary heart disease in type 2 diabetes
    Gorshunska, M.
    Karachentsev, I.
    Atramentova, L.
    Krasova, N.
    Tyzhnenko, T.
    Pochernyaev, A.
    Leshchenko, Z.
    Fedorova, G.
    Gladkih, A.
    Kravchun, N.
    Khizhnyak, O.
    Poltorak, V.
    DIABETOLOGIA, 2009, 52 : S522 - S523
  • [45] STUDIES ON ISCHEMIC HEART DISEASE IN PATIENTS WITH DIABETES MELLITUS
    OHASHI, K
    MAEDA, M
    HIROSHIM.A
    MATOBA, N
    TAMURA, K
    KIMOTSUK.K
    TANIWA, M
    OKAMOTO, K
    MORIMOTO, T
    YAMAGAMI, T
    SHIMADA, Y
    MORI, I
    ISHIKURA, Y
    WADA, M
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1968, 32 (12S): : 1856 - &
  • [46] Therapy of Type 2 Diabetes Mellitus in Patients with Heart Disease
    Kerner, W.
    Motz, W.
    AKTUELLE KARDIOLOGIE, 2013, 2 (01) : 17 - 23
  • [47] Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure
    Johansson, Isabelle
    Dahlstrom, Ulf
    Edner, Magnus
    Nasman, Per
    Ryden, Lars
    Norhammar, Anna
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (13) : 1404 - 1416
  • [48] Paraoxonase genotypes and activity and oxidized LDL in type 2 diabetes mellitus: relationship with vascular complications
    Lucchesi, D.
    Pucci, L.
    Longo, V.
    Triscornia, S.
    Fotino, C.
    Penno, G.
    Del Prato, S.
    Miccoli, R.
    DIABETOLOGIA, 2008, 51 : S474 - S475
  • [49] Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
    Atamer, Y.
    Atamer, A.
    Can, A. S.
    Hekimoglu, A.
    Ilhan, N.
    Yenice, N.
    Kocyigit, Y.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2013, 46 (06) : 528 - 532
  • [50] Achalasia Is Associated With Lower Prevalence of Ischemic Heart Disease and Diabetes Mellitus Type II
    Sawas, Tarek
    Katzka, David A.
    GASTROENTEROLOGY, 2016, 150 (04) : S459 - S459